Virax Biolabs Group Balance Sheet

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Year Ending	TTM	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Cash & Equivalents	5.11	9.35	0.02	0.02	0.02
Cash & Cash Equivalents	5.11	9.35	0.02	0.02	0.02
Cash Growth	43646.85%	42888.32%	23.47%	-22.06%	-
Receivables	0	0	0	0	0
Inventory	0.02	0	0.02	0.02	0
Other Current Assets	0.84	0.28	0.01	0	0
Total Current Assets	5.97	9.63	0.05	0.04	0.02
Property, Plant & Equipment	0.68	0	0	0	0
Goodwill and Intangibles	0.37	0.18	0	0	0
Total Long-Term Assets	1.05	0.18	0	0	0
Total Assets	7.03	9.81	0.05	0.04	0.02
Accounts Payable	0.74	0.72	1.24	0.87	1.03
Deferred Revenue	0	0.04	0	0	0
Current Debt	0.05	0.15	0	0	0
Other Current Liabilities	0	0	0	0	0.21
Total Current Liabilities	0.79	0.91	1.25	0.87	1.24
Long-Term Debt	0.13	0	0	0	0
Total Long-Term Liabilities	0.13	0	0	0	0
Total Liabilities	0.92	0.91	1.25	0.87	1.24
Total Debt	0.18	0.15	0	0	0
Debt Growth	81.71%	-	-	-	-
Retained Earnings	-14.8	-11.79	-6.34	-4.63	-3.98
Comprehensive Income	0.04	-0	-0	-0	0
Shareholders' Equity	6.33	9.13	-0.97	-0.65	-1.06
Net Cash / Debt	4.93	9.21	0.02	0.02	0.02
Net Cash / Debt Growth	-	42216.09%	23.47%	-22.06%	-
Net Cash Per Share	2.77	8.66	0.02	0.07	0.22
Working Capital	5.18	8.73	-1.2	-0.83	-1.22
Book Value Per Share	3.57	8.59	-1.02	-2.71	-10.12

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).